Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cell immune awakening in response to immunotherapy is age-dependent.
Salih Z, Banyard A, Tweedy J, Galvani E, Middlehurst P, Mills S, Weightman J, Gupta A, Lorigan PC, Zhou C, Dhomen N, Valpione S, Marais R. Salih Z, et al. Among authors: marais r. Eur J Cancer. 2022 Feb;162:11-21. doi: 10.1016/j.ejca.2021.11.015. Epub 2021 Dec 21. Eur J Cancer. 2022. PMID: 34952479 Free PMC article.
New insight into BRAF mutations in cancer.
Dhomen N, Marais R. Dhomen N, et al. Among authors: marais r. Curr Opin Genet Dev. 2007 Feb;17(1):31-9. doi: 10.1016/j.gde.2006.12.005. Curr Opin Genet Dev. 2007. PMID: 17208430 Review.
Oncogenic Braf induces melanocyte senescence and melanoma in mice.
Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Dhomen N, et al. Among authors: marais r. Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022. Cancer Cell. 2009. PMID: 19345328 Free article.
BRAF signaling and targeted therapies in melanoma.
Dhomen N, Marais R. Dhomen N, et al. Among authors: marais r. Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001. Hematol Oncol Clin North Am. 2009. PMID: 19464601 Review.
A mouse model of melanoma driven by oncogenic KRAS.
Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, Marais R. Milagre C, et al. Among authors: marais r. Cancer Res. 2010 Jul 1;70(13):5549-57. doi: 10.1158/0008-5472.CAN-09-4254. Epub 2010 Jun 1. Cancer Res. 2010. PMID: 20516123 Free PMC article.
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME. Eisen T, et al. Among authors: marais r. Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750549 Free PMC article. Clinical Trial.
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R. Girotti MR, et al. Among authors: marais r. Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14. Cancer Discov. 2013. PMID: 23242808 Free PMC article.
259 results